상세 보기
SARS-CoV-2 Breakthrough Infections after Introduction of 4 COVID-19 Vaccines, South Korea, 2021
- Yi, Seonju;
- Choe, Young June;
- Kim, Jia;
- Kim, Yoo-Yeon;
- Kim, Ryu Kyung;
- 외 7명
Citations
WEB OF SCIENCE
6Citations
SCOPUS
6초록
We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
키워드
VACCINATION
- 제목
- SARS-CoV-2 Breakthrough Infections after Introduction of 4 COVID-19 Vaccines, South Korea, 2021
- 저자
- Yi, Seonju; Choe, Young June; Kim, Jia; Kim, Yoo-Yeon; Kim, Ryu Kyung; Jang, Eun Jung; Lim, Do Sang; Byeon, Hye Ryeon; Lee, Sangwon; Park, Eonjoo; Kim, Seung-Jin; Park, Young-Joon
- 발행일
- 2022-03
- 유형
- Letter
- 권
- 28
- 호
- 3
- 페이지
- 753 ~ 756